Efficacy was demonstrated Allegra a significant reduction in mean pruritus scores (MPS), mean number of wheals (MNW), and mean total symptom scores (MTSS, the sum of the MPS and MNW score). Statistically significant reductions in symptom scores were observed following the first 60 mg dose, with the effect maintained throughout the 12-hour interval. The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy subjects. Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine Allegra .
Fexofenadine hydrochloride was rapidly absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.
In these studies, there was no additional reduction in total symptom scores with higher doses of fexofenadine hydrochloride up to 240 mg twice daily. Although the number of subjects in some of the subgroups was small, there were no significant differences in the effect of fexofenadine hydrochloride across subgroups of subjects defined by gender, age, and race. The 60 mg twice daily dose did not provide any additional Allegra D Tablets over the 30 mg twice daily dose in pediatric subjects 6 to 11 years of age. Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily). Symptom reduction was greater with fexofenadine hydrochloride180 mg than with placebo. It is freely soluble in methanol and ethanol, slightly soluble in chloroform and water, and insoluble in hexane. The tablet formulations are bioequivalent to the capsule when administered at equal doses. This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models.